PHILADELPHIA, PA — Context Therapeutics (Nasdaq: CNTX) amended its licensing agreement with BioAtla (Nasdaq: BCAB) to eliminate future milestone and royalty payments tied to its CT-202 cancer program, a move that gives the biotechnology company full economic rights to a drug candidate it considers increasingly central to its oncology pipeline.
Under the revised agreement, Context will pay BioAtla $4.5 million upfront and an additional $2.0 million by August 1, 2026, in exchange for removing all future payment obligations related to CT-202.
The transaction simplifies the economics surrounding Context’s Nectin-4 x CD3 T-cell engager program as the company advances the therapy through clinical development in solid tumors, an increasingly competitive segment of cancer immunotherapy.
Chief Executive Officer Martin Lehr characterized CT-202 as an increasingly important asset within the company’s development portfolio and indicated the amendment improves Context’s ability to retain future value from the program.
CT-202 is a bispecific antibody designed to direct T cells toward cancer cells expressing Nectin-4, a protein frequently overexpressed in several solid tumors including bladder, colorectal, lung, and breast cancers.
Nectin-4 has already been validated as a cancer target through antibody-drug conjugate therapies, though existing approaches have been associated with adverse effects including neuropathy and rash.
Context’s therapy uses a pH-dependent design intended to activate preferentially within the tumor microenvironment, an approach aimed at improving targeting precision while potentially reducing systemic toxicity.
The amendment modifies an exclusive license agreement originally executed between the companies in September 2024.
Support the local news that supports Chester County. MyChesCo delivers reliable, fact-based reporting and essential community resources—free for everyone. If you value that, click here to become a patron today.